Raloxifene: a new choice for treating and preventing osteoporosis.
Selective estrogen receptor modulators (SERMs) are a new class of drugs that provide a new option for addressing the health challenges of postmenopausal women. This review discusses the proposed mechanism of action of SERMs and describes clinical findings on raloxifene, a SERM now available for treating and preventing osteoporosis.
Licata
A A
AA
Department of Endocrinology, Cleveland Clinic, OH 44195, USA. licataa@ccf.org
Ciaccia
A V
AV
Wong
M
M
Draper
M W
MW
D000368:Aged; D002116:Calcitonin / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control*; D017698:Postmenopause; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*
D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002116:Calcitonin